These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 28613442)
1. The effect of different immunoprophylaxis regimens on post-transplant cytomegalovirus (CMV) infection in CMV-seropositive liver transplant recipients. Low CY; Hosseini-Moghaddam SM; Rotstein C; Renner EL; Husain S Transpl Infect Dis; 2017 Oct; 19(5):. PubMed ID: 28613442 [TBL] [Abstract][Full Text] [Related]
2. Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients. Luan FL; Samaniego M; Kommareddi M; Park JM; Ojo AO Transpl Infect Dis; 2010 Dec; 12(6):473-9. PubMed ID: 20576019 [TBL] [Abstract][Full Text] [Related]
3. Low-dose valganciclovir for cytomegalovirus prophylaxis in intermediate-risk liver transplantation recipients. Khan S; Sullivan T; Ali M; Dunn D; Patel G; Huprikar S Liver Transpl; 2018 May; 24(5):616-622. PubMed ID: 29500912 [TBL] [Abstract][Full Text] [Related]
4. Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: a possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation. Ruggenenti P; Codreanu I; Cravedi P; Perna A; Gotti E; Remuzzi G Clin J Am Soc Nephrol; 2006 May; 1(3):546-54. PubMed ID: 17699258 [TBL] [Abstract][Full Text] [Related]
5. Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation. Flaman F; Zieroth S; Rao V; Ross H; Delgado DH J Heart Lung Transplant; 2006 Nov; 25(11):1358-62. PubMed ID: 17097501 [TBL] [Abstract][Full Text] [Related]
6. Acyclovir versus valganciclovir for preventing cytomegalovirus infection in intermediate-risk liver transplant recipients. McKeen JT; Tsapepas DS; Li H; Anamisis A; Martin ST Prog Transplant; 2015 Mar; 25(1):39-44. PubMed ID: 25758799 [TBL] [Abstract][Full Text] [Related]
7. Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection. Deeks ED; Keating GM Drugs; 2009 Jul; 69(11):1483-512. PubMed ID: 19634926 [TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus in renal transplant recipients from living donors with and without valganciclovir prophylaxis and with immunosuppression based on anti-thymocyte globulin or basiliximab. Andrade-Sierra J; Heredia-Pimentel A; Rojas-Campos E; Ramírez Flores D; Cerrillos-Gutierrez JI; Miranda-Díaz AG; Evangelista-Carrillo LA; Martínez-Martínez P; Jalomo-Martínez B; Gonzalez-Espinoza E; Gómez-Navarro B; Medina-Pérez M; Nieves-Hernández JJ Int J Infect Dis; 2021 Jun; 107():18-24. PubMed ID: 33862205 [TBL] [Abstract][Full Text] [Related]
10. The effect of anti-thymocyte globulin and everolimus on the kinetics of cytomegalovirus viral load in seropositive kidney transplant recipients without prophylaxis. Basso G; Felipe CR; Cristelli MP; Mansur Siliano J; Viana L; Ferreira Brigido AN; Stopa Martins SB; de Castro Lima Santos DW; Aguiar WF; Tedesco-Silva Junior H; Medina-Pestana JO Transpl Infect Dis; 2018 Aug; 20(4):e12919. PubMed ID: 29797676 [TBL] [Abstract][Full Text] [Related]
11. Different impact of rATG induction on CMV infection risk in D+R- and R+ KTRs. Kaminski H; Jarque M; Halfon M; Taton B; Di Ascia L; Pfirmann P; Visentin J; Garrigue I; Déchanet-Merville J; Moreau JF; Crespo E; Montero N; Melilli E; Meneghini M; Pascual M; Couzi L; Manuel O; Bestard O; Merville P J Infect Dis; 2019 Jul; 220(5):761-771. PubMed ID: 31157865 [TBL] [Abstract][Full Text] [Related]